Arovella Therapeutics Ltd (ALA) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.090x

Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) has a cash flow conversion efficiency ratio of -0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.71 Million ≈ $-1.21 Million USD) by net assets (AU$18.92 Million ≈ $13.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Arovella Therapeutics Ltd market capitalisation for the company's overall valuation and market capitalisation.

Arovella Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Arovella Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Arovella Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Arovella Therapeutics Ltd ranked by their cash flow conversion efficiency. See Arovella Therapeutics Ltd (ALA) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Diatreme Resources Ltd AU:DRX	-0.020x
Classic Scenic Bhd KLSE:7202	-0.046x
Syntek Semiconductor Co Ltd TWO:5302	0.004x
EITA Resources Bhd KLSE:5208	0.038x
180 Degree Capital Corp NASDAQ:TURN	-0.083x
Euro Sun Mining Inc TO:ESM	0.204x
CTCBIO Inc KQ:060590	0.079x
OFS Capital Corp NASDAQ:OFS	0.154x

Annual Cash Flow Conversion Efficiency for Arovella Therapeutics Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Arovella Therapeutics Ltd from 2013 to 2025. View Arovella Therapeutics Ltd (ALA) stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$20.08 Million ≈ $14.21 Million	AU$-6.93 Million ≈ $-4.90 Million	-0.345x	+43.94%
2024-06-30	AU$11.23 Million ≈ $7.94 Million	AU$-6.91 Million ≈ $-4.89 Million	-0.616x	+63.62%
2023-06-30	AU$3.78 Million ≈ $2.67 Million	AU$-6.40 Million ≈ $-4.53 Million	-1.692x	-105.66%
2022-06-30	AU$7.62 Million ≈ $5.39 Million	AU$-6.27 Million ≈ $-4.44 Million	-0.823x	-108.53%
2021-06-30	AU$8.98 Million ≈ $6.36 Million	AU$-3.54 Million ≈ $-2.51 Million	-0.395x	+43.41%
2020-06-30	AU$4.14 Million ≈ $2.93 Million	AU$-2.88 Million ≈ $-2.04 Million	-0.697x	-290.58%
2019-06-30	AU$13.98 Million ≈ $9.89 Million	AU$-2.50 Million ≈ $-1.77 Million	-0.179x	+19.67%
2018-06-30	AU$11.46 Million ≈ $8.11 Million	AU$-2.55 Million ≈ $-1.80 Million	-0.222x	-338.46%
2017-06-30	AU$16.85 Million ≈ $11.92 Million	AU$-854.22K ≈ $-604.42K	-0.051x	+53.29%
2016-06-30	AU$16.61 Million ≈ $11.75 Million	AU$-1.80 Million ≈ $-1.28 Million	-0.109x	+33.60%
2015-06-30	AU$19.30 Million ≈ $13.66 Million	AU$-3.15 Million ≈ $-2.23 Million	-0.163x	+0.04%
2014-06-30	AU$15.99 Million ≈ $11.32 Million	AU$-2.61 Million ≈ $-1.85 Million	-0.164x	+32.03%
2013-06-30	AU$6.69 Million ≈ $4.73 Million	AU$-1.61 Million ≈ $-1.14 Million	-0.241x	--

About Arovella Therapeutics Ltd

AU:ALA Australia Biotechnology

Market Cap

$49.61 Million

AU$70.11 Million AUD

Market Cap Rank

#22011 Global

#774 in Australia

Share Price

AU$0.06

Change (1 day)

-1.69%

52-Week Range

AU$0.06 - AU$0.10

All Time High

AU$0.57